CD19 and acute lymphoblastic leukemia: In a recent meta-analysis on 953 patients treated with tisagenlecleucel (Kymriah®) (58) (a CD19-directed CAR T-cell therapy which is approved and commercially available for R/R BCP-ALL in patients aged 1–25 years), no differences in outcome were seen across the different age groups.